07.03.19

Gemini version available ♊︎

The European Patent Office is Disconnected From the Rule of Law and European Media Could Not Care Less

Posted in Europe, Law, Patents at 6:15 am by Dr. Roy Schestowitz

Europe’s corporate media refuses to touch important subjects

Europe's corporate media news cycle

Summary: Public interests aren’t served but harmed by today’s European Patent Office, but somehow we’re supposed to think that EPO scandals are ‘old news’ (even when courts repeatedly highlight these problems)

THE lawlessness at the European Patent Office (EPO) prevails. It doesn’t matter who’s in charge, nobody really oversees the leadership. Nobody. Definitely not the European press, which deliberately ignores all the scandals (especially Campinos scandals, more so than Battistelli scandals).

It’s as if everything is now rosy and absolutely perfect. Nobody is complaining. Nobody in the media speaks to actual EPO staff and Battistelli’s corruption is treated as an already-addressed fiasco (‘addressed’ by virtue of his term coming to an end and the throne being passed to a friend).

“Nobody in the media speaks to actual EPO staff and Battistelli’s corruption is treated as an already-addressed fiasco (‘addressed’ by virtue of his term coming to an end and the throne being passed to a friend).”“Roufousse T. Fairfly” commented on this new article regarding EUIPO and CJEU (very high court). “For patent law, Art. 53a EPC as revised in 2000 specifically disconnects European patents from national law or practice,” s/he said (we assume it’s a pseudonym, hence gender uncertain), but as even EPO insiders are certainly aware, the EPO violates the EPC very routinely so nothing governs what it does, certainly not the ‘bought’ Council (which ‘represents’ members states’ interest in money, not justice). The full comment:

When I read dusty old GRUR bound in volumes I would occasionally come across reports on trade mark decisions. The outcome at German national courts generally seemed to hinge on whether the alleged profanity is in a foreign language (e.g., English), in which case it could be registered, as the average person wouldn’t necessarily understand it, IIRC.

Regarding the reference to “national bodies” in the opinion: There are two DE trade marks in the DPMA database, but these appear to be spurious applications made by squatters, and they have been withdrawn. I don’t believe that it’s possible to see whether any morality objection was raised, as, IIRC, third parties must demonstrate a “legitimate interest” (“berechtigtes Interesse”) to gain access to trade mark files, and these are usually destroyed some time after the extinction of rights.

For patent law, Art. 53a EPC as revised in 2000 specifically disconnects European patents from national law or practice:

European patents shall not be granted in respect of: inventions the commercial exploitation of which would be contrary to “ordre public” or morality; such exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation in some or all of the Contracting States;

Morals and patents are two different things anyway…

The way things stand, many “immoral” patents are being granted; maybe “unethical” would be a better term. We recently named some of these patents and law scholars from Europe have just published this paper entitled A European View on the Patent Eligibility of Biomedical Diagnostic Methods” (published less than a week ago). Their view of the US position as summarised in their abstract:

The Supreme Court’s decisions in Mayo, Myriad and Alice, as well as the CAFC’s in Roslin focused widespread attention on the formulation of patent-eligibility exclusions for specific biological material and diagnostic methods.

The debate recently intensified with the CAFC’s Sequenom decision and denial of a rehearing en banc. The claims at issue in U.S. Patent No. 6,258,540 (“US ’540 patent”) are directed to methods of genetic testing by detecting and amplifying paternally inherited fetal cell-free DNA (cffDNA) from maternal blood and plasma. Before the development of this non-invasive prenatal diagnostic test, patients were placed at higher risk and maternal plasma was routinely discarded as waste.

A reluctant CAFC formulaically interpreted the Supreme Court-devised bifurcated test to identify patent ineligible subject matter and invalidated the patent for this ground-breaking method. Notably, Judge Linn wrote that this innovation deserves patent protection, but that the “sweeping language of the test” established in Mayo requires a determination that the claims are patent ineligible. On March 21, 2016 Sequenom Inc. filed for certiorari and the issue may once again find itself at the Supreme Court. As framed by Sequenom, the question presented is:

Whether a novel method is patent-eligible where: (1) a researcher is the first to discover a natural phenomenon; (2) that unique knowledge motivates him to apply a new combination of known techniques to that discovery; and (3) he thereby achieves a previously impossible result without preempting other uses of the discovery?

Interestingly, in Europe the EPO upheld essentially the same claims. European equivalents of the patents considered in Myriad, Mayo, Alice and Roslin were also treated differently than in the US. Hence, these cases undermine the global integration of patent standards and provide fodder for discussing patentability requirements at an international level.

Referring to these developments, our paper discusses these issues from a comparative European perspective. Section 1 provides a very brief summary of the European patent framework and case law regarding medical diagnostic methods. Leaving aside national peculiarities that would exceed the limitations of this study we focus on the EPO’s patent eligibility approach vis-à-vis medical diagnostic methods similar to those in Sequenom v. Ariosa. Section 2 discusses our findings and the differences between the US and European approaches from a broader innovation and patent policy perspective providing the basis for concluding remarks in section 3.

Mayo and Myriad relate to patenting of life and nature, as per these SCOTUS decisions that gave rise to 35 U.S.C. § 101 as we know it (and USPTO chooses not to know it, unlike courts such as the Federal Circuit, referred to above as “CAFC”). It is rather worrying that the world moves in a direction such as this; should patents be granted on things that always existed or predate humans?

Ellie Purnell (HGF Ltd) has just published this piece aboutA Further Referral To The Enlarged Board Of Appeal On Plants Produced By Essentially Biological Processes” (by Campinos).

Patent extremists were upset that Campinos was entertaining this because in their minds every granted patent must never be questioned or doubted. But the way we see it, Campinos made a mistake by entertaining this because there was no need for it. No reason for this. Highest of all authorities in Europe, not to mention the EPC (yes, law notwithstanding, even if the EPO no longer obeys laws!), already told EPO management to stop granting these illegal patents (but of course the EPO won’t listen!). In Purnell’s words:

In decision T1063/18, a EPO Technical Board of Appeal created controversy in ruling that the jurisprudence of the Enlarged Board of Appeal took precedence over Rule 28(2) of the EPC. The Board held that decisions G2/12 and G2/13 should be followed in preference to the rule, thus allowing claims to plants produced by essentially biological processes.

T1063/18 created uncertainty as to how the EPO would deal with this conflict; were examiners to follow the rules or the Board’s precedent? Many expected that the EPO would have to take action to clarify the legal situation, and many hoped that there would be a referral to the Enlarged Board of Appeal. This has now happened.

To give a little more background, we first reported back in December 2018 on T1063/18 that the Board considered that controversial R.28(2) EPC is in conflict with A.53(b) EPC, as interpreted in both the Enlarged Board decisions G2/12 and G2/13 (“broccoli II” and “tomatoes II”), and was therefore improper. As a result of this, the Board held that R.28(2) EPC should be ignored, and that plants produced by essentially biological processes are indeed patentable. Our full article can be found here.

As we noted in our previous post, the Enlarged Board of Appeal and other appeal board still lack independence. This is chaotic because there’s not even a sense or appearance of powers being separated. So we can imagine what the outcome will be (or what severe consequences will follow if judges ‘defy’ the king, Mr. Campinos). Isobel Finnie (Haseltine Lake Kempner LLP) has meanwhile commented on patents of questionable legitimacy or patents which — in her words — “involv[e] additional or improved treatments using already known drugs.” (This is sometimes known as evergreening, perpetuating monopolies to deny emergence of generics — generic drugs or generic treatments)

Deciding when to file a patent application can be a difficult decision. If you file a patent application too early there may not be enough information in the application as filed to convincingly show that the invention will work as proposed. However, waiting too long can mean that more prior art is citable against the patent application and it can be harder to show novelty and inventiveness. This balancing act is particularly difficult for second medical use type patents.

Second medical use claims are used before the European Patent Office (EPO) for inventions involving additional or improved treatments using already known drugs. For example, using a known drug to treat a different disease or changing the dosage regimen of a known drug to provide a better effect or to treat a different patient group. In the context of second medical use claims the EPO has made it clear that the therapeutic effect must be made plausible (in the sense of being very credible to a skilled reader) from the information in the patent document. This can play a part in assessing whether the new treatment claimed as the invention is sufficiently disclosed, and for assessing whether the problem of providing the treatment as claimed has been solved. The patent specification needs to contain enough information, and this usually means data from experiments from some stage during the drug development process, to make the therapeutic effect plausible.

“Second Medical Use Patents” (as she put it) aren’t good for patients, only for patents. And they typically mean more deaths. It’s all about profits, or about pure greed. There’s both a moral and ethical dilemma at hand here.

Sandeep Basra, her (Finnie’s) colleague, has meanwhile taken note of European Patents which European courts are rejecting. Whose patent is the latest? An American company that became notorious for price-fixing cartels and price gouging. To quote:

The German Federal Patent Court found the German part of the Eli Lilly patent, EP 1 313 508 B in the first instance to be void. An appeal against this decision has now been filed at the German Federal Court of Justice.

It’s more of the same. European Patents quite so often turn out to be ‘fake’ these days (when courts actually assess these, not bullied examiners and scared judges on EPO premises… or in exile at Haar… one foot away from unemployment).

The EPO is in a very bad shape not for financial reasons (a lie basically); the problem is brain drain, which relates to reputation harm, declining prestige of European Patents, and sloppy examination euphemised as “Collaborative Quality Improvements” (CQI).

Share in other sites/networks: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Reddit
  • email

Decor ᶃ Gemini Space

Below is a Web proxy. We recommend getting a Gemini client/browser.

Black/white/grey bullet button This post is also available in Gemini over at this address (requires a Gemini client/browser to open).

Decor ✐ Cross-references

Black/white/grey bullet button Pages that cross-reference this one, if any exist, are listed below or will be listed below over time.

Decor ▢ Respond and Discuss

Black/white/grey bullet button If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

DecorWhat Else is New


  1. Gemini Gone Mainstream: German Media Now in Geminispace

    With the likes of TAZ embracing Geminispace/Gemini Protocol we seem to have reached some sort of inflection point; taz.de did in fact add official presence to Geminispace



  2. Links 28/1/2022: LSFMM 2022 and 2021 UI Study Results From Elementary's Distro

    Links for the day



  3. IRC Proceedings: Thursday, January 27, 2022

    IRC logs for Thursday, January 27, 2022



  4. Links 28/1/2022: GNU Poke 2.0 and OPNsense 22.1 Released

    Links for the day



  5. Links 27/1/2022: Archinstall 2.3.1 and Nix 2.6.0

    Links for the day



  6. On the Internet, Trust Should Not Become Centralised

    “Trust” is a word that lost its meaning in the era of “TPM” and fancier names for 'Palladium'; we need to reject this idea that computers need to check with Microsoft if the operating system is trusted (not just Windows!), check with Gulag/Chrome if a Web site is trusted, and whether it's OK to run some application/s on one's own computer (as if Jim Zemlin et al get to decide what is trusted)



  7. Microsoft-Connected Publishers Suffer and Perish With Microsoft (While Peddling 'Fake News' for Their Beloved Sponsor)

    IDG and other fake news outlets/networks/sites (selling to companies flattering articles about themselves or renting out 'news space' to them, not just ad space) want us to think Microsoft is doing very well, but it's just that same old Ponzi scheme



  8. Links 27/1/2022: Mabox Linux 21.11 Herbolth and PipeWire 0.3.44

    Links for the day



  9. IRC Proceedings: Wednesday, January 26, 2022

    IRC logs for Wednesday, January 26, 2022



  10. [Meme] EPO: Pursuing an Eastern and Western District of Europe (for Patent Trolls and Software Patents)

    With the EPO so flagrantly lying and paying for misinformation maybe we should expect Benoît Battistelli and António Campinos to have delusions of grandeur… such as presiding over the Eastern and Western District of Europe, just like Mr. Gilstrap and Mr. Albright (political appointment by Donald Trump, ushering in “the swamp”)



  11. Gemini at 2,000: 86% of Capsules Use Self-Signed Certificate, Just Like the Techrights Web Site (WWW)

    As shown in the charts above (updated an hour ago), the relative share of ‘Linux’ Foundation (LE/LF; same thing, same office) in the capsules’ certificates has decreased over time; more and more (in terms of proportion) capsules choose to sign their own certificate/s; the concept of ‘fake security’ (centralisation and consolidation) should be rejected universally because it leaves nobody safe except plutocrats



  12. [Meme] UPC: Many Lies as Headlines, Almost Exclusively in Publishers Sponsored by EPO and Team UPC to Produce Fake News (Lobbying Through Misinformation)

    Lest we forget that EPO dictators, like Pinky and the Brainless Benoît Battistelli and António Campinos, have long littered the EPO's official Web site as well as publishers not directly connected to the EPO (but funded by it) with disinformation about the UPC



  13. EPO as the 'Ministry of Truth' of Team UPC and Special Interests

    The 'Ministry of Truth' of the patent world is turning the EPO's Web site into a propaganda mill, a misinformation farm, and a laughing stock with stock photography



  14. Microsoft 'Delighted' by Windows 11 (Vista 11) Usage, Which is Only 1% Three Months After Official Launch and Six Months After Release Online

    Microsoft boosters such as Bogdan Popa and Mark Hachman work overtime on distraction from the failure Vista 11 has been (the share of Windows continues to fall relative to other platforms)



  15. Links 27/1/2022: Preinstalled GNU/Linux (Ubuntu) and Arch Linux-Powered Steam Deck 30 Days Away

    Links for the day



  16. Don't Fall for Microsoft's Spin That Says Everything is Not Secure and Cannot be Secured

    Microsoft keeps promoting the utterly false concept that everything is not secure and there's nothing that can be done about it (hence, might as well stay with Windows, whose insecurity is even intentional)



  17. At Long Last: 2,000 Known Gemini Capsules!

    The corporate media, looking to appease its major sponsors (such as Web/advertising giants), won't tell you that Gemini Protocol is rising very rapidly; its userbase and the tools available for users are rapidly improving while more and more groups, institutions and individuals set up their own capsule (equivalent of a Web site)



  18. Links 26/1/2022: Gamebuntu 1.0, PiGear Nano, and Much More

    Links for the day



  19. IRC Proceedings: Tuesday, January 25, 2022

    IRC logs for Tuesday, January 25, 2022



  20. Links 26/1/2022: No ARM for Nvidia, End of EasyArch, and WordPress 5.9 is Out

    Links for the day



  21. Why the Unified Patent Court (UPC) is Still Just a Fantasy and the UPC's Fake News Mill Merely Discredits the Whole Patent 'Profession'

    Patents and science used to be connected; but now that the patent litigation 'sector' is hijacking patent offices (and even courts in places like Texas) it's trying to shove a Unified Patent Court (UPC) down the EU's throat under the disingenuous cover of "community" or "unity"



  22. Links 25/1/2022: Vulkan 1.3 Released, Kiwi TCMS 11.0, and antiX 19.5

    Links for the day



  23. Gemini Milestones and Growth (Almost 2,000 Known Gemini Servers Now, 39,000 Pages in Ours)

    The diaspora to Gemini Protocol or the transition to alternative 'webs' is underway; a linearly growing curve suggests that inertia/momentum is still there and we reap the benefits of early adoption of Gemini



  24. [Meme] Get Ready for Unified Patent Court (UPC) to be Taken to Court

    The Unified Patent Court (UPC) and Unitary Patent system that’s crafted to empower EPO thugs isn’t legal and isn’t constitutional either; even a thousand fake news 'articles' (deliberate misinformation or disinformation) cannot change the simple facts because CJEU isn’t “trial by media”



  25. The EPO Needs High-Calibre Examiners, Not Politicians Who Pretend to Understand Patents and Science

    Examiners are meant to obstruct fake patents or reject meritless patent applications; why is it that working conditions deteriorate for those who are intellectually equipped to do the job?



  26. Free Software is Greener

    Software Freedom is the only way to properly tackle environmental perils through reuse and recycling; the mainstream media never talks about it because it wants people to "consume" more and more products



  27. Links 25/1/2022: Git 2.35 and New openSUSE Hardware

    Links for the day



  28. IRC Proceedings: Monday, January 24, 2022

    IRC logs for Monday, January 24, 2022



  29. Links 25/1/2022: GPL Settlement With Patrick McHardy, Godot 4.0 Alpha 1, and DXVK 1.9.4 Released

    Links for the day



  30. Proprietary Software is Pollution

    "My daughter asked me about why are we throwing away some bits of technology," Dr. Andy Farnell says. "This is my attempt to put into words for "ordinary" people what I tried to explain to a 6 year old."


RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

Recent Posts